Nanocarriers for drug delivery applications

Chamundeeswari, M.; Jeslin, J.; Verma, Madan L.

doi:10.1007/s10311-018-00841-1

Cited by 246 publications

(158 citation statements)

References 167 publications

Supporting

Mentioning

137

Contrasting

Unclassified

Order By: Relevance

“…The common Plasmodium species that result in drug resistance is P. falciparum . It causes life-threatening symptoms such as cerebral malaria, anemia, severe fever, adult respiratory distress syndrome, seizure, disseminated intravascular coagulation, and coma [ 28 ]. The antimalarial drugs suffer from drug resistance when Plasmodium parasites survive and grow in the presence of administered drugs that are usually used to destroy and inhibit their growth.…”

Section: Antimalarial Drugsmentioning

confidence: 99%

“…The antimalarial drugs suffer from drug resistance when Plasmodium parasites survive and grow in the presence of administered drugs that are usually used to destroy and inhibit their growth. The following factors influence the drug resistance which is common with most antimalarial drugs: pharmacokinetic mismatch of antimalarial drugs, poor patient compliance and incorrect dosage [ 28 ].…”

Section: Antimalarial Drugsmentioning

confidence: 99%

“…Some nanocarriers include nanoparticles [ 20 ], dendrimers [ 21 ], nanomicelles [ 22 ], polymer-drug conjugates [ 23 ], hydrogels [ 24 ], nanogels [ 25 ], nanocapsules [ 26 ], and nanoliposomes [ 27 ], have been designed for the incorporation of artemisinin and its derivatives. These nanocarriers are very useful in the field of drug delivery [ 28 ]. The advantages of nanocarriers in the field of oncology and parasitic infections (such as malaria and leishmaniasis) include reduced/non-drug toxicity, the overcoming of drug resistance, improved aqueous drug solubility, enhanced bioavailability and pharmacokinetics, specific-site drug delivery, drug cellular internalization etc.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Nanoparticles Formulations of Artemisinin and Derivatives as Potential Therapeutics for the Treatment of Cancer, Leishmaniasis and Malaria

Alven

Aderibigbe

2020

Pharmaceutics

View full text Add to dashboard Cite

Cancer, malaria, and leishmaniasis remain the deadly diseases around the world although several strategies of treatment have been developed. However, most of the drugs used to treat the aforementioned diseases suffer from several pharmacological limitations such as poor pharmacokinetics, toxicity, drug resistance, poor bioavailability and water solubility. Artemisinin and its derivatives are antimalarial drugs. However, they also exhibit anticancer and antileishmanial activity. They have been evaluated as potential anticancer and antileishmanial drugs but their use is also limited by their poor water solubility and poor bioavailability. To overcome the aforementioned limitations associated with artemisinin and its derivatives used for the treatment of these diseases, they have been incorporated into nanoparticles. Several researchers incorporated this class of drugs into nanoparticles resulting in enhanced therapeutic outcomes. Their potential efficacy for the treatment of parasitic infections such as malaria and leishmaniasis and chronic diseases such as cancer has been reported. This review article will be focused on the nanoparticles formulations of artemisinin and derivatives for the treatment of cancer, malaria, and leishmaniasis and the biological outcomes (in vitro and in vivo).

show abstract

Section: Antimalarial Drugsmentioning

confidence: 99%

Section: Antimalarial Drugsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Nanoparticles Formulations of Artemisinin and Derivatives as Potential Therapeutics for the Treatment of Cancer, Leishmaniasis and Malaria

Alven

Aderibigbe

2020

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Among different drug delivery systems, nanoparticles (NPs) have been widely studied for their unique chemical, physical and biological properties as well as their clinical applications [ 12 ]. Regarding their composition, NPs can be classified as organic or inorganic nanoparticles [ 13 ], and many of them, especially liposomes and polymeric NPs, have been approved for the treatment of different pathologies, such as Doxil ® (Janssen, 1995) or Plegridy ® (Biogen, 2014) for the therapy of ovarian cancer and multiple sclerosis, respectively [ 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Increasing Brain Permeability of PHA-767491, a Cell Division Cycle 7 Kinase Inhibitor, with Biodegradable Polymeric Nanoparticles

et al. 2021

View full text Add to dashboard Cite

A potent cell division cycle 7 (CDC7) kinase inhibitor, known as PHA-767491, has been described to reduce the transactive response DNA binding protein of 43 KDa (TDP-43) phosphorylation in vitro and in vivo, which is one of the main proteins found to aggregate and accumulate in the cytoplasm of motoneurons in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) patients. However, the main drawback of this compound is its low permeability to the central nervous system (CNS), limiting its use for the treatment of neurological conditions. In this context, the use of drug delivery systems like nanocarriers has become an interesting approach to improve drug release to the CNS. In this study, we prepared and characterized biodegradable nanoparticles in order to encapsulate PHA-767491 and improve its permeability to the CNS. Our results demonstrate that poly (lactic-co-glycolic acid) (PLGA) nanoparticles with an average radius between 145 and 155 nm could be used to entrap PHA-767491 and enhance the permeability of this compound through the blood–brain barrier (BBB), becoming a promising candidate for the treatment of TDP-43 proteinopathies such as ALS.

show abstract

“…AuNPs are widespread nanocarriers in biomedical applications, due to their stability, ease of surface functionalization, and unique optical properties (Verma et al 2020). AuNPs can be used to target tumor-specific sites through passive accumulation, due to their enhanced permeability and retention (EPR), or through functionalization with an active-targeting molecule (Chamundeeswari et al 2019). Recently, EGCG-AuNPs showed a selective inhibitory efficacy in human smooth muscle cells, and the cellular internalization of EGCG-AuNPs within short periods of time was associated with laminin receptor-mediated endocytosis (Khoobchandani et al 2016, Shukla et al 2012.…”

Section: Introductionmentioning

confidence: 99%

Epigallocatechin gallate-capped gold nanoparticles enhanced the tumor suppressors let-7a and miR-34a in hepatocellular carcinoma cells

Mostafa

Gamal‐Eldeen

Maksoud

et al. 2020

An. Acad. Bras. Ciênc.

View full text Add to dashboard Cite

Nanocarriers for drug delivery applications

Cited by 246 publications

References 167 publications

Nanoparticles Formulations of Artemisinin and Derivatives as Potential Therapeutics for the Treatment of Cancer, Leishmaniasis and Malaria

Nanoparticles Formulations of Artemisinin and Derivatives as Potential Therapeutics for the Treatment of Cancer, Leishmaniasis and Malaria

Increasing Brain Permeability of PHA-767491, a Cell Division Cycle 7 Kinase Inhibitor, with Biodegradable Polymeric Nanoparticles

Epigallocatechin gallate-capped gold nanoparticles enhanced the tumor suppressors let-7a and miR-34a in hepatocellular carcinoma cells

Contact Info

Product

Resources

About